Concepedia
Statistics
Publications
7
Citations
141
H-Index
Active since
2016
Affiliations
Eli Lilly (United States)(Current)
UCB Pharma (Belgium)
Novartis (United States)
Pfizer (United States)
GlaxoSmithKline (United States)
Matthew M. Abernathy is an author at Eli Lilly (United States) specializing in medicine, patient safety, and public health.
Top concepts
MedicinePublic HealthPatient SafetyCardiologyHematologyPopulationThrombosisEpidemiologyAnesthesiologyCardiac Arrest
Publications per year
2016–2023
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
Annie Delaunois, Matthew M. Abernathy, Warren D. Anderson et al. · Clinical and Translational Science · 2021 · 34 citations · Full text
Revisiting the hERG safety margin after 20 years of routine hERG screening
Derek J. Leishman, Matthew M. Abernathy, Evan B. Wang · Journal of Pharmacological and Toxicological Methods · 2020 · 31 citations
Preventive Medicine, Cancer Screening, Patient Safety +7
Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure
Petra Verdino, Stacey L. Lee, Fariba N. Cooper et al. · British Journal of Pharmacology · 2023 · 25 citations · Full text
A Case of Successful Thromboelastographic Guided Resuscitation after Postpartum Hemorrhage and Cardiac Arrest
Maurice Hurwich, D. Zimmer, E. Guerra et al. · Journal of ExtraCorporeal Technology · 2016 · 15 citations · Full text
Trauma Resuscitation, Vascular Trauma, Prehospital Resuscitation +18
A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium
Emmanuel Boulay, Matthew M. Abernathy, Ray W. Chui et al. · International Journal of Toxicology · 2018 · 15 citations · Full text
1–5 of 7